From Benzinga’s Global Small Cap Conference: Yield10 Biosciences President & CEO, Oliver Peoples Says Co Has Really High Profit Margins
https://www.youtube.com/watch?v=XkOilNZqoEI
From Benzinga’s Global Small Cap Conference: Yield10 Biosciences President & CEO, Oliver Peoples Says Co Has A $4 Billion Annual Camelina Products Revenue Potential By 2030
https://www.youtube.com/watch?v=XkOilNZqoEI
Yield10 Shares Quiet Following Tweet From Co. ‘CEO Dr. Oliver Peoples spoke to Farm World on Congress approving $10 billion in disaster relief for farmers. He explains how we need to have sustainable food production…’
https://twitter.com/Yield10Bio/status/1468594797694881797
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Yield10 Bioscience Tweets ‘$YTEN is committed to global food security, but with the ongoing pandemic and climate change affecting crops, consumers may notice shortages of their favorite grocery products.’
https://twitter.com/Yield10Bio/status/1456264196052508672
Yield10 Bioscience’s Return On Capital Employed Overview
Benzinga Pro data, Yield10 Bioscience (NASDAQ:YTEN) reported Q2 sales of $174.00 thousand. Earnings fell to a loss of $3.08 million, resulting in a 20.73% decrease from last quarter.
Recap: Yield10 Bioscience Q2 Earnings
Shares of Yield10 Bioscience (NASDAQ:YTEN) moved higher by 3.2% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 14.67% over the past year to ($0.64), which missed the estimate of ($0.54).